Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MEDI7352 in Healthy Japanese and Caucasian Subjects
NCT04770428Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2021
- Primary completion
- Dec 2021
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MEDI7352 in knee osteoarthritis (OA) (4 arms), sponsored by AstraZeneca. Primary endpoint: Number of participants with adverse events at Day 84. Started Apr 2021; status: completed.
02
Drugs
MEDI7352
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04770428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04770428.